[Arthropathies following the administration of pefloxacin to an adolescent with mucoviscidosis].
We report the occurrence of knee joint effusion with prolonged functional impairment in a 17-year old boy with cystic fibrosis treated with pefloxacin for recurrent lower respiratory tract infections caused by Pseudomonas aeruginosa. Because the quinolone pefloxacin fairly often induces joint disease in pediatric age groups, we advocate restricting its use to those patients whose growth is completed. In growing individuals, it seems reasonable to use second generation quinolones only in infections caused by resistant organisms and to avoid exerting the joints during treatment.
Kesseler
A
A
Lacassie
A
A
Hugot
J P
JP
Talon
P
P
Thomas
D
D
Astier
L
L
D000293:Adolescent; D003550:Cystic Fibrosis / Q000150:complications*; D006801:Humans; D007592:Joint Diseases / Q000139:chemically induced*; D007719:Knee Joint; D008297:Male; D015366:Pefloxacin / Q000009:adverse effects*; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology
D015366:Pefloxacin
Arthropathies consécutives à l'administration de péfloxacine chez un adolescent atteint de mucoviscidose.